ClinicalTrials.gov
ClinicalTrials.gov Menu

Transfusion Requirements After Orthotopic Liver Transplantation (TROLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01435746
Recruitment Status : Unknown
Verified September 2011 by Armin Goralczyk, University Medical Center Goettingen.
Recruitment status was:  Not yet recruiting
First Posted : September 19, 2011
Last Update Posted : September 19, 2011
Sponsor:
Information provided by (Responsible Party):
Armin Goralczyk, University Medical Center Goettingen

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this trial is to evaluate different transfusion strategies in patients after liver transplantation. Patients in the experimental arm will be given red blood cell (RBC) transfusion according to a liberal strategy, i. e., transfusions should be given, when hemoglobin concentration falls below 10 g/dl, and hemoglobin concentration should be maintained between 10 and 12 g/dl. Patients in the control arm will be given red blood cell (RBC) transfusion according to a restrictive strategy, i. e., transfusions should be given, when hemoglobin concentration falls below 8 g/dl, and hemoglobin concentration should be maintained between 8 and 10 g/dl.

Condition or disease Intervention/treatment Phase
Anemia Behavioral: Red blood cell transfusion Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Pilot Trial of Transfusion Requirements After Orthotopic Liver
Study Start Date : November 2011
Estimated Primary Completion Date : November 2012
Estimated Study Completion Date : November 2013

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Liberal Transfusion
Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
 Behavioral: Red blood cell transfusion
The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
Active Comparator: Conservative Transfusion
Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
 Behavioral: Red blood cell transfusion
The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Composite of death, graft loss and renal failure [ Time Frame: 30 days after randomization ]

Secondary Outcome Measures :
  1. Renal function [ Time Frame: 30 days after randomization ]
    Renal function will be assessed by estimated glomerular filtration rate


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing liver transplantation
  • Patients considered to have euvolemia after initial treatment by attending physicians

Exclusion Criteria:

  • Patients age 18 or less
  • Patients undergoing combined liver-kidney transplantation
  • Patients requiring renal replacement therapy before liver transplantation for longer than two weeks
  • Inability to receive blood products
  • Patient with active blood loss at the time of enrollment
  • Pregnancy
  • Imminent death
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01435746


Contacts
Contact: Armin D Goralczyk, Dr. +49 551 398490 agoralczyk@med.uni-goettingen.de
Contact: Aiman Obed, Prof. +49 551 398490 aobed@med.uni-goettingen.de

Locations
Germany
University Medical Center Göttingen Not yet recruiting
Göttingen, Niedersachsen, Germany, 37075
Contact: Armin D Goralczyk, Dr.    +49 551 398490    agoralczyk@med.uni-goettingen.de   
Sub-Investigator: Aiman Obed, Prof.         
Principal Investigator: Thomas Lorf, Dr.         
Sponsors and Collaborators
University Medical Center Goettingen
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Armin Goralczyk, Dr., University Medical Center Goettingen
ClinicalTrials.gov Identifier: NCT01435746     History of Changes
Other Study ID Numbers: TROLL11
First Posted: September 19, 2011    Key Record Dates
Last Update Posted: September 19, 2011
Last Verified: September 2011

Keywords provided by Armin Goralczyk, University Medical Center Goettingen:
liver transplantation
intensive care
red blood cell transfusion